Protara Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Protara Therapeutics, Inc. (TARA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 1.39% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-10
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was 1.39%, a 504.35% increase from fiscal 2024.
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.23%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | 1.39% 10-K · filed 2026-03-10 |
| 2024-12-31 | 0.23% 10-K · filed 2026-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |